PHARMEXCIL, Indian Govt Discuss Measures To Strengthen India’s Pharma Exports

The Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) has held a series of high-level meetings with senior government officials to align policy priorities and identify growth opportunities aimed at strengthening India’s pharmaceutical exports.

The PHARMEXCIL delegation, comprising chairman Namit Joshi, chairman of iPHEX 2026 and the MSME Committee Nipun Jain, and director general Raja Bhanu, met Rajesh Agrawal, secretary in the Department of Commerce and Industry, to review export performance and discuss measures to sustain global market expansion.

During the meeting, the delegation highlighted that India’s pharmaceutical exports reached $30.47 billion in FY 2024–25, reflecting year-on-year growth of 9.4 percent, and indicated that exports are on track to exceed the previous year’s levels. PHARMEXCIL also noted that it ranks fourth among all export promotion councils in terms of export performance, underlining the sector’s contribution to India’s overall trade.

The council acknowledged the Department’s support for initiatives such as the Chintan Shivir programme, a series of regional conferences aimed at engaging pharmaceutical MSMEs, with upcoming editions planned in Ahmedabad and Hyderabad. Officials were also briefed on iPHEX 2026, scheduled to be held from September 7 to 9, 2026, at Bharat Mandapam in New Delhi.

In a separate meeting with Manoj Joshi, secretary in the Department of Pharmaceuticals, discussions focused on the sector’s growth outlook. While pharmaceutical exports have reached $30.47 billion, India’s domestic pharma market, currently valued at around $60 billion, is projected to expand to $130 billion by 2030.

The delegation also outlined India’s position as the world’s third-largest pharmaceutical producer by volume, supplying affordable, quality-assured medicines to more than 150 countries. Talks with Satya Prakash L, joint secretary in the Department of Pharmaceuticals, centred on strengthening industry–academia collaboration across clinical trials, biopharmaceuticals, vaccines and active pharmaceutical ingredients, with emphasis on innovation, skills development and capacity building.

PHARMEXCIL also met Lav Aggarwal, director general of foreign trade, to provide an overview of its key initiatives and seek continued support for programmes including Chintan Shivir and iPHEX 2026.

Also Read